Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Human LRRC15 / LIB Protein, His Tag (MALS verified)

LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma) . LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE) -containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

Product Specifications

Background

LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma) . LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE) -containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

Specifications

This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 59.7 kDa. The protein migrates as 55-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Accession Number

Q8TF66-1

Expression Region

Tyr 22 - Gly 538

Host

CHO

Target

LRRC15

Conjugation

Unconjugated

Tag

C-10xHis

Source

Human

Stability

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Endotoxin

1.0 EU per μg

Purity

90%

Bioactivity

Immobilized Human LRRC15 Protein, His Tag (Cat. No. LR5-H51H3) at 2 μg/mL (100 μL/well) can bind Samrotamab with a linear range of 0.4-13 ng/mL (QC tested).

Format

Powder

Buffer

PBS, pH7.4

Additives

Trehalose

Molecular Weight

59.7 kDa

Additionnal Information

Please see 'Shipping-and-Payments' sheet. Website: https://www.acrobiosystems.com/support/shipping-and-payments

Shipping Conditions

RT

Storage Conditions

-20°C

Package Size

100ug*1

Host or Source

CHO

Species

Human

Protein ID

Q8TF66-1

Preservative

Trehalose

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

HXB7 Antibody
C44159-01 50 μL

HXB7 Antibody

Ask
View Details
HXB7 Antibody
C44159-02 100 µL

HXB7 Antibody

Ask
View Details
PDE6D Human
OM298232-01 20 µg

PDE6D Human

Ask
View Details
PDE6D Human
OM298232-02 5 µg

PDE6D Human

Ask
View Details
PDE6D Human
OM298232-03 1 mg

PDE6D Human

Ask
View Details
Recombinant Mouse TACI Protein, hFc Tag
32-17955-50 50 µg

Recombinant Mouse TACI Protein, hFc Tag

Ask
View Details